Apolipoprotein L1 nephropathies: 2017 in review

Jeffrey B. Kopp, Hila Roshanravan, Koji Okamoto

研究成果: Review article査読

5 被引用数 (Scopus)

抄録

Purpose of review To review publications relating to apolipoprotein L1 (APOL1) renal risk variants published 2017. Recent findings The study of APOL1 variants continues to be highly active; 24 articles published in 2017 were selected to highlight. These include clinical studies of kidney disease, kidney transplantation, hypertension, cardiovascular disease, and genetic diversity. Laboratory studies included APOL1 association with vesicle-associated membrane soluble N-ethylmaleimide-sensitive factor activating protein receptor protein and with soluble urokinase-type plasminogen activator receptor, mitochondrial dysfunction, endolysosomal dysfunction, and inflammasome activation. Summary Our understanding of the role of APOL1 genetic variants and the mechanisms for renal toxicity continues to deepen. It is not yet clear which pathways are most relevant to human disease, and so, the most relevant drug targets remain to be defined.

本文言語English
ページ(範囲)153-158
ページ数6
ジャーナルCurrent Opinion in Nephrology and Hypertension
27
3
DOI
出版ステータスPublished - 2018 5月 1
外部発表はい

ASJC Scopus subject areas

  • 内科学
  • 腎臓病学

フィンガープリント

「Apolipoprotein L1 nephropathies: 2017 in review」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル